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Abstract 
Parkinson disease (PD) is a neurodegenerative 
disorder characterized by fibrillar neuronal 
inclusions composed of aggregated α-synuclein. 
These inclusions are associated with behavioral 
and pathological PD phenotypes. One strategy for 
therapeutic interventions is to prevent the 
formation of these inclusions in order to halt 
disease progression. α-Synuclein exists in multiple 
structural forms, including disordered, non-
amyloid oligomers, ordered amyloid oligomers, 
and fibrils. It is critical to understand which 
conformers contribute to specific PD phenotypes. 
Here, we utilized a mouse model to explore the 
pathological effects of stable amyloid β-sheet 
oligomers compared with those of fibrillar α-
synuclein. We biophysically characterized these 
species with transmission EM, atomic-force 
microscopy, CD spectroscopy, FTIR spectroscopy, 
analytical ultracentrifugation, and thioflavin T 
assays. We then injected these different α-
synuclein forms into the mouse striatum to 
determine their ability to induce PD-related 
phenotypes. We found that β-sheet oligomers 
produce a small but significant loss of dopamine 
neurons in the substantia nigra pars compacta 
(SNc). Injection of small β-sheet fibril fragments, 
however, produced the most robust phenotypes, 
including reduction of striatal dopamine terminals, 
SNc loss of dopamine neurons, and motor 
behavior defects. We conclude that although the β-
sheet oligomers cause some toxicity, the potent 
effects of the short fibrillar fragments can be 
attributed to their ability to recruit monomeric α-
synuclein and spread in vivo and hence contribute 
to the development of PD-like phenotypes. These 
results suggest that strategies to reduce the 
formation and propagation of β-sheet fibrillar 
species could be an important route for therapeutic 
intervention in PD and related disorders.  
________________________________________ 
Multiple neurodegenerative diseases are 
characterized by amyloid inclusions that are 
formed by the assembly of monomeric proteins 
into oligomeric intermediates that then grow to 
form protofilaments, and eventually fibrils (1). In 
Parkinson disease (PD), these inclusions are 
referred to as Lewy bodies and Lewy neurites and 
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are composed primarily of α-synuclein (2), but 
also include other proteins such as p62 and 
ubiquitin (3). They develop from the nucleated 
polymerization of endogenous α-synuclein that is 
then thought to spread within neurons and to 
propagate to interconnected neuronal networks in 
a spatially and temporally predictable manner 
(4,5). The role of α-syn in neurodegeneration and 
in generating symptoms in PD is not yet 
completely clear and is an area of active research. 
It is important to note that neurodegeneration is 
likely to be caused by a combination of factors in 
addition to α-synuclein inclusion formation such 
as impaired proteostasis, mitochondrial 
dysfunction, and activation of the inflammatory. 
On the basis of data that support the cell-to-cell 
spreading of α-synuclein aggregates, however, 
therapeutic strategies such as immunotherapy are 
in development in the hope of blocking the 
invasion of pathogenic α-synuclein species into 
additional brain regions and hence slowing the 
progression of PD (6).   
Preventing the progression of α-synuclein 
inclusion formation, however, requires precise 
definitions of the species that are more highly 
toxic, and those that are capable of promoting the 
formation of new aggregates by recruiting 
endogenous monomeric α-synuclein. Assemblies 
of structurally diverse oligomers and fibrils have 
varying degrees of pathogenicity (7-9). In a 
cellular environment, monomeric α-synuclein 
interacts with membranes, and adopts an α-helical, 
tetrameric conformation (10-12). Monomeric α-
synuclein can also assemble into fibrils in an array 
of heterogeneous oligomeric species that are often 
transient in nature. Recently, methods have been 
developed to produce and stabilize oligomers of α-
synuclein (7,13), enabling these to be extensively 
characterized. One particularly well defined type 
of α-synuclein oligomeric species is composed of 
approximately 15-30 protein molecules, adopts a 
spherical appearance, and contains a rudimentary 
β-sheet structural core with very limited capability 
of binding the amyloid-specific dye thioflavin T 
(ThioT) and of elongating and recruiting new α-
synuclein molecules. Addition of these oligomers 
to cells in culture disrupts membranes, generates 
reactive oxygen species, increases cytosolic 
calcium, and increases cell death (7,13,14). In 
contrast, the typical fibrillar forms of α-synuclein 
show the general amyloid features, including 
ability to bind ThioT, the presence of a cross-β 
core structure and an elongated filamentous 
morphology of 10-15 nm of diameter.  Exposure 
of neurons to extracellular α-synuclein fibrils 
induces intracellular endogenous α-synuclein to 
form inclusions that are morphologically and 
biochemically similar to those found in diseased 
brains; they form dense Lewy body-like 
aggregates in the soma, thread-like Lewy-neurites 
in the neuropil, are insoluble in nonionic 
detergents, are primarily composed of fibrillar 
aggregates, and are phosphorylated, ubiquitinated, 
and proteinase K resistant (4,5,15,16). Inclusion 
formation leads to loss of dopaminergic neurons in 
the SNc with associated motor dysfunctional 
phenotypes, recapitulating the core features of PD. 
It has been shown that extensive sonication of α-
synuclein fibrils increases the abundance of 
inclusions (17,18). Such fragmentation, however, 
can generate a heterogeneous ensemble of species, 
including oligomers as well as short and long 
fibrillar fragments, which likely contributes to the 
current variability of observed phenotypes in the 
pre-formed fibril (PFF) mouse model (19). More 
precise biophysical characterization combined 
with in vivo experiments is required to define 
which species contribute more strongly to the 
neuropathological and neurodegenerative 
phenotypes.  
Here, we produce, isolate, and define 
reproducible conformers of mouse α-synuclein and 
monitor the neuropathological and 
neurodegenerative outcomes in mice injected with 
of different well-defined forms of the protein, 
namely monomers, stable kinetically-trapped β-
sheet oligomers and fibril fragments. Unilateral 
injection of the β-sheet oligomers causes a slight, 
but significant loss of dopamine neurons in the 
SNc, but does not induce inclusion formation or 
produce defects in motor behavior; these findings 
can be attributable to the inability of these 
oligomers to grow by addition of the monomeric 
protein. The injections of preparations of short 
fibrils (70 nm), however, results in the formation 
of inclusions, the loss of dopamine terminals in the 
striatum, dopaminergic neurons in the SNc, and 
motor behavior defects.  
Results 
Biophysical and morphological characterization 

















In order to determine the capacity of 
different structural forms of α-synuclein in the 
mouse brain to induce PD-related phenotypes, we 
used recombinant mouse α-synuclein protein for 
the preparations of the different forms given the 
lower efficiency of seeding when using cross-
species (i.e., human) α-synuclein forms ((20); see 
Figure 3). We first characterized the stability and 
structural features of oligomers and fibrils.  α-
Synuclein fibrils were generated by shaking 
monomeric α-synuclein for seven days at 37°C, 
and the resulting structures showed by 
transmission electron microscopy (TEM) and 
atomic force microscopy (AFM) indicated a long, 
filamentous structure as observed previously (“F-
Long, F-L”) with an average length of 266  0.5 
nm (Figure 1A-D). Shorter fibrils were then 
generated by sonication reducing the average 
length to 120  4.0 nm; these fragments still, 
however, varied in length from 40-225 nm (“F-
Mix, F-M”) (Figure 1E-H). Samples enriched in 
shorter fragments were generated by passing the 
solution of F-M through a 0.22 µm filter (21,22), 
resulting in an average length of 70  3.3 nm and a 
more homogenous distribution of 40-125 nm (“F-
short, “F-S) (Figure 1I-L). Stabilized oligomeric 
species were generated using the procedure 
described previously for the human variant of the 
protein (7,14); these oligomers were observed in 
TEM and AFM images to have a spherical 
morphology that was similar to that observed for 
oligomers generated by human α-synuclein. Their 
size was more uniform than that of the fibrillar 
samples, with an average length of 54  0.7 nm 
and a range of 40-70 nm (Figure 1M-P). To 
confirm that the procedures used to generate the 
oligomers and fibrils did not cause degradation of 
α-synuclein, oligomer, F-L, F-M, and F-S were 
incubated with urea to dissociate the fibrils and 
oligomers into monomers. α-Synuclein was 
identified using SDS-PAGE and bands were 
visualized using either “instant blue” or silver 
stain.  Protein remains unaltered in all the protein 
samples, except for some minor monomer 
degradation occurred in the oligomeric samples 
with minimal consequences for the study 
(Supplemental Figure 1).  
Indeed, the stable, purified oligomers 
generated by mouse α-synuclein show identical 
morphological and structural features as the 
previously reported oligomers of human α-
synuclein (Figure 2A)(7). As previously shown for 
human oligomers, analytical ultracentrifugation 
(AUC) revealed that mouse oligomers showed two 
main distributions: one centered at 10S 
corresponding to a population of oligomers 
composed of an average of 18 α-synuclein 
molecules (260 kDa) and the other at 15 S, 
corresponding to oligomers composed of an 
average of 29 α-synuclein molecules (420 kDa) 
(Figure 2A), and similar to the size distribution of 
human oligomers. Also similar to the previously 
characterized human oligomers, mouse oligomers 
showed an intermediate structure between the 
disordered monomer and the β-sheet rich amyloid 
fibrils, with an average of 30% of β-sheet structure 
(F-L, F-M and F-S show  60-65%) according to 
Fourier transform infrared (FTIR) and far-UV 
circular dichroism (CD) spectroscopy analysis 
(7,13) (Figure 2B,C). They also showed a 
marginal ability to bind ThioT molecules (Figure 
2D), unlike F-L, F-M and F-S, which show similar 
ThioT binding. In addition, the FTIR data also 
showed a marked difference between the 
oligomers and the fibrils; while the spectra of the 
fibrils contain an absorbance peak at 1,620 cm-1 
and no absorbance peak at 1695 cm-1, 
characteristic of a parallel β-sheet configuration, 
the spectra of the oligomers clearly show both 
peaks demonstrating an antiparallel β-sheet 
arrangement. An antiparallel conformation for 
stabilized oligomers and parallel conformation for 
fibrils has previously been observed for human α-
synuclein, and other amyloidogenic proteins and 
peptides such as amyloid-β (23,24), and the 
acquisition of the antiparallel β-sheet arrangement 
has been associated with a lower structural 
stability and a significantly reduced efficiency in 
elongation and seeding (7,25). Indeed, the stable 
oligomeric species (O) of α-synuclein appear to be 
trapped species that need to dissociate and 
reassemble into species with parallel β-sheet 
structure to readily assemble into fibrils. 
Antibodies have been generated which recognize 
toxic conformations of proteins implicated in 
neurodegeneration (26,27). The A11 antibodies 
selectively recognize potentially toxic 
conformations of proteins implicated in 
neurodegeneration, particularly pre-fibrillar 
oligomers, whereas OC recognizes fibrils. Dot-

















expected, OC recognized FL, FM and FS. A11 
recognized the oligomer preparation but also 
recognized the sonicated fibrils. A11, however, 
did not recognize the long fibrils (Supplemental 
Figure 2). These data indicate that the process of 
fragmenting longer fibrils can produce toxic 
oligomers as previously shown (13). 
 
Seeding efficiency of fibrils and oligomers in 
vitro and in neurons 
We first wanted to assess the degree of 
compatibility between human and mouse α-
synuclein in in vitro seeding reactions (Figure 3A). 
Mouse and human fibrils (5µM) were combined 
with 100µM mouse α-synuclein monomer, and the 
formation of ThioT positive amyloid fibrils was 
measured over time. Mouse fibrils seeded the 
formation of ThioT-positive amyloid fibrils from 
mouse α-synuclein monomer more rapidly than 
human fibrils as previously shown (20). 
Interestingly, the initial rate of seeding using 
fibrils and monomers of human α-synuclein 
protein was slower than that observed for mouse 
α-synuclein and was significantly slower when 
mouse α-synuclein fibrils were used to seed 
solutions of human α-synuclein monomers. Thus, 
the seeding efficiency was found to be higher 
when the species of α-synuclein seeds matches 
that of the free monomers; therefore, in the in vivo 
seeding studies that involve endogenous 
expression of mouse α-synuclein, it is 
recommended to use fibrillar seeds generated from 
mouse α-synuclein.  
Using the mouse protein, the ability of the 
oligomers and the different sizes of fibrils to seed 
formation of ThioT-positive amyloid fibrils was 
also determined (Figure 3B). Seeding with the 
oligomers was highly inefficient and produced 
negligible fibril formation over time, a finding 
consistent with previous data for the human 
protein showing that these oligomers are trapped 
in a conformation distinct from that of the fibrillar 
species that is unable to efficiently elongate (7). In 
contrast, all the fibrillar samples used in this study 
were highly efficient in the seeding reactions. 
To examine the ability of different α-
synuclein fibrils to seed inclusion formation in 
neurons, 0.05 µM concentrations of monomeric, 
O, F-L, F-M or F-S were added to wild type 
primary hippocampal neurons and the abundance 
of phosphorylated α-synuclein, a marker of 
pathological α-synuclein inclusion formation in 
cells, was measured (28) (Figure 3C,D). Neither 
monomeric nor oligomeric α-synuclein was found 
to produce p-α-synuclein inclusions, a result 
consistent with the finding that these forms of α-
synuclein were not able to seed fibril formation in 
vitro. Immunofluorescence appeared diffuse and 
faint in experiments with both forms of α-
synuclein. F-M and F-S produced similar 
quantities of inclusions, the majority of which 
appeared as bright and thread-like structures 
similar to Lewy-neurites found in 
synucleinopathies brains.  In contrast, a small 
quantity of p-α-synuclein was visible in neurons 
exposed to the long fibrils; significantly lower 
compared to the levels observed in neurons 
exposed to fragmented fibrils (Figure 3C,D). To 
determine if fibrils are more efficient at inducing 
α-synuclein inclusion formation because they are 
more efficiently internalized than oligomers, an 
internalization assay using α-synuclein labeled 
with Alexa488 was performed (29). This assay 
utilizes trypan blue to quench the fluorescence of 
extracellular α-synuclein conformers to distinguish 
extracellular from intracellular α-synuclein. In 
addition, when trypan blue binds to proteins on the 
membrane surface, it fluoresces when excited at 
560nm, allowing visualization of soma and 
neurites. Both short Alexa488 labelled α-synuclein 
fibrils (F-S) and oligomers (O) were internalized, 
while unsonicated fibrils showed minimal 
internalization  as demonstrated previously (29) 
(Figure 3E). Surprisingly, oligomers showed 
significantly increased internalization compared to 
fibrils, indicating that efficiency of fibril uptake 
does not account for robust inclusion formation. 
Table 1 summarizes the structural and 
morphological features of all the α-synuclein 
species used in this study. 
 
Formation of inclusions in the brain by fibrils 
and oligomers 
To determine the extent to which the 
oligomers and the different lengths of fibrils seed 
the formation of α-synuclein inclusions in the 
brain, mice received unilateral striatal injections of 
each species with the mass concentrations in the 
samples measured immediately after injection. 
Monomeric α-synuclein was also injected as a 
control. In the case of the oligomeric samples, the 

















absorbance at 280 nm (the extinction coefficient 
used was 8278 M-1cm-1 for oligomers); the 
fibrillar samples were first dissociated into 
monomeric units using guanidinium hydrochloride 
and the concentration of protein in the sample was 
then determined (the extinction coefficient used 
was 7450 M-1cm-1). The concentration of the 
oligomers was determined to be 300 µM, and that 
of F-L, F-M, and F-S to be 150 µM, although the 
fibrils were initially prepared using 300 µM α-
synuclein. Since this study was initiated, we 
published a recommendation that fibrils should be 
freshly made before injections, rather being frozen 
and that the concentration of fibrils should be 
measured immediately before injection (19). Thus, 
the concentration of oligomers injected was twice 
that of the fibrils in terms of monomer equivalents. 
The mice were perfused 3 months after 
injection of the α-synuclein species. 
Immunohistochemistry was performed using an 
antibody specific for α-synuclein phosphorylated 
at serine-129, one of the post-translational 
modifications of α-synuclein in Lewy neurites and 
Lewy bodies in synucleinopathy brains (28).  In 
synucleinopathy models, there is very little 
pSer129-α-synuclein in neurons from control wild 
type mice. However, exposure of neurons to 
fibrils, produces α-synuclein abundant inclusions 
that are highly phosphorylated (5). These fibril-
induced inclusions have also been shown in 
previous studies to be ubiquitin and p62 positive, 
and are insoluble in detergent (5,16,30-32).  
Importantly, when neurons from α-synuclein 
knockout mice are exposed to fibrils, the neurons 
show minimal pSer129-α-synuclein 
immunoreactivity (4). In both monomer and 
oligomer injected mice (Figure 4A) 
immunoreactivity for p-α–synuclein appeared to 
be diffuse in the cytosol, possibly representing a 
pool of monomeric α–synuclein protein targeted 
for degradation (33). Unilateral striatal injections 
of F-L, F-M, and F-S all resulted in the formation 
of p-α-synuclein positive inclusions that produced 
more intense signals compared to oligomer 
injected mice. The inclusions appeared as Lewy-
neurite like threads in the neuropil and skein-like 
inclusions in the soma. The abundance of neurons 
with inclusions in the soma was measured using a 
semi-quantitative rating scale (Supplemental 
Figure 3) and the average level within the animals 
in each group was calculated. Table 2 shows the 
list of the brain areas containing inclusions along 
with a ranking based on the quantification process 
in the different brain areas. The brain areas with 
the most abundant inclusions included the cortex, 
amygdala and striatum.  Except for the SNc, which 
only showed inclusions on the side ipsilateral to 
the injection, all the brain areas investigated 
showed bilateral inclusions after unilateral 
injections of α-synuclein species in the striatum, 
although the ipsilateral side consistently showed 
more inclusions than the contralateral side (Figure 
4C). The fragmented fibrils (F-M, F-S) produced 
significantly more inclusions than non-fragmented 
fibrils (F-L), although there were no significant 
differences in the abundance of inclusions between 
F-M and F-S injected mice (Figure 3).    
Appearance of p-α-synuclein inclusions in 
different brain regions at different time points 
following injections of fibrillar species   
The most abundant inclusions appear in the 
cortex, amygdala, and SNc. These brain regions all 
project to the striatum (34), suggesting that the 
aggregates are internalized into the axon terminals, 
and the resulting inclusions spread within the 
neuron to the soma. This is consistent with 
findings that after addition of fibrils to neurons of 
nontransgenic mice endogenously expressing α-
synuclein, inclusions appear first in axons and then 
at later time points in the soma (4), and is also 
consistent with the highest concentration of α-
synuclein being at the presynaptic terminals (35).  
To confirm the observation that inclusions appear 
in brain nuclei that project to the striatum, we co-
injected the fibrillar samples with retrotracer beads 
into the right dorsal-lateral striatum. Neither the 
retrotracer beads nor p-α-synuclein-positive 
inclusions had appeared in the SNc (Figure 5A) or 
amygdala one week after injections. In the cortex, 
however, small fluorescent p-α-synuclein puncta 
that were colocalized with retrotracer beads were 
visible. Two weeks after injection, however, p-α-
synuclein-positive inclusions were visible in the 
SNc, cortex and amygdala in the same area as the 
retrotracer beads. By four weeks after injection, p-
α-synuclein-positive inclusions were abundant in 
all three brain regions. These data show that the 
formation of p-α-synuclein-positive inclusions 
after injection of fibrils is not apparent until about 
one week after injections and that the cortex is the 


















Loss of dopamine terminals in the striatum and 
dopamine neurons in the SNc  
Unilateral injection of sonicated fibrils into the 
striatum was previously shown to produce a 
significant, approximately 35%, loss of 
dopaminergic neurons in the SNc relative to mice 
injected with saline solution (5). The loss occurred 
6 months following injection of fibrils, whereas 
there were no statistically significant differences in 
the numbers of tyrosine hydroxylase (TH)-positive 
dopamine neurons 3 months after injection. We 
used, here, unbiased stereology to quantify the 
numbers of TH-positive neurons in the ipsilateral 
and contralateral SNc of mice unilaterally injected 
with the different α-synuclein species. Three 
months after injection, only F-S produced a 
significant, approximately 30% loss of 
dopaminergic neurons compared to monomer 
injected mice in the ipsilateral SNc (Figure 6). The 
number of dopaminergic neurons on the side 
ipsilateral to the injection site were significantly 
reduced relative to the non-injected side (Figure 
6B). Oligomers produced a significant reduction in 
the number of neurons on the side ipsilateral to the 
injection site relative to the non-injected side. To 
determine if dopamine neurons are dying in mice 
injected with α-synuclein species, or if TH levels 
are simply being downregulated, double labeling 
immunofluorescence measurements for TH and 
NeuN (Supplemental Figure 4) was performed in 
the SNc. Compared to mice that received 
unilateral injections of monomeric α-synuclein, 
there was a slight, but not statistically significant, 
reduction in the number of NeuN positive neurons 
in the mice that received unilateral injections of F-
S. The TH-immunofluorescence in the F-S and O-
injected mice appeared beaded compared to 
monomer injected mice, suggestive of dying 
neurons. However, there were also TH-positive 
neurons that appeared healthy. These findings 
suggest the existence TH-positive-dopaminergic 
and non-dopaminergic neuron subtypes in the SNc 
that resist toxic α-synuclein fibrils.  
The loss of dopamine terminals from the 
striatum was measured by immunofluorescence 
detection of the dopamine transporter (DAT) 
(Figure 6 C,D). Mice injected with both F-M and 
F-S showed a significant, approximately 30%, 
reduction in DAT-positive dopamine terminals 
relative to monomer injected mice. However, only 
F-M injected mice showed a statistically 
significant loss of TH-positive axons in the SNc 
(Supplemental Figure 5). The difference between 
DAT and TH labeling in the striatum could simply 
result from technical differences in 
immunofluorescence labeling, or differences 
between vesicular localized DAT vs. cytosolic 
localized TH. Alternatively, the possible 
interaction between α-synuclein aggregates and 
DAT may alter the trafficking and localization of 
this transporter, which could potentially be an 
interesting line of investigation for the future.  In 
addition, unlike the unilateral loss of dopamine 
neurons in the SNc, the loss of dopamine terminals 
in the striatum was bilateral. Thus, smaller fibrils 
of α-synuclein cause a loss of dopamine neurons 
and dopamine terminals at 3 months following 
injections.  
  
Motor behavior defects caused by fibrils and 
oligomers 
We next determined if injection of fibrils 
and the consequent loss of dopaminergic neurons 
and terminals were associated with defects in 
motor behavior. After 3 months, only mice that 
received unilateral injections of F-S showed a 
significant increase relative to untreated mice in 
the time needed to descend a pole, a well-
established test for “bradykinesia” (36) (Figure 7). 
Using the cage hang test, a test of motor strength, 
it was found that only F-S injected mice also 
dropped from the lid of a cage in consistently 
shorter times compared to control mice, also 
indicative of motor defects (5). There were no 
significant differences among any of the groups of 
treated mice in an open field test for time spent in 
the center of the field (a measure of “anxiety) or in 
the speed of movement. A cylinder test modified 
specifically for mice (37) also showed no 
differences among the groups in the average 
numbers of hind limb steps or rears. Injections of 
short fragments of fibrils, therefore, show much 
greater defects in behavioral tests of bradykinesia 
and motor strength compared to much larger 
fibrils and toxic but propagation-deficient 
oligomers.   
 
Discussion 
Designing therapeutic strategies to halt the 
progression and spread of synucleinopathies such 

















forms of α-synuclein that are responsible for given 
phenotypes, including the formation of inclusions 
in multiple brain areas, the loss of dopamine 
terminals, the reduction in the numbers of neurons 
in the SNc, and the loss of normal motor behavior.  
In the present study, we have used a combination 
of biophysical, biochemical and behavioral assays 
to demonstrate that small aggregates composed 
primarily of small fragments of α-synuclein fibrils 
are able to induce typical features of PD when 
injected into the brains of healthy mice. Such 
aggregates are able to grow and recruit 
endogenous monomeric α-synuclein, suggesting 
that these species are important agents for the 
spreading of toxicity and disease. By contrast, 
stable oligomeric aggregates of α-synuclein, which 
do not undergo elongation, were unable to induce 
the formation of inclusions by endogenous α-
synuclein, to cause loss of dopamine terminals in 
the striatum, to cause loss of dopamine neurons in 
the SNc, or to cause deficiencies in motor 
behavior. The oligomers, however, caused a 
significant loss of dopamine neurons in the SNc on 
the side ipsilateral to the injection compared to the 
contralateral side, a finding consistent with their 
established cytotoxic nature but lack of seeding 
potency (7,14,38,39). Considering all the present 
results together, we demonstrate that other 
properties, in addition to toxicity, such as the 
ability of aggregates to seed the formation of new 
aggregates and to spread between cells, are 
important for the induction of PD phenotypes in an 
animal model, and that the α-synuclein species 
that are most efficient in spreading pathology are 
small fibrillar aggregates, and particularly fibrillar 
oligomers with high seeding efficiency. Indeed our 
results suggest that the ability of aggregated 
species to recruit monomeric protein molecules 
and to generate new toxic aggregates is a more 
important feature than the inherent toxicity of the 
injected species for the development of PD-related 
phenotypes (i.e. highly toxic, seeding-deficient 
oligomers vs. less toxic and seeding competent 
small fibrils). In addition, our results suggest that 
the major disease spreading agents consist of 
seeding-efficient α-synuclein small fibrillar 
aggregates rather than the possible specific 
conformers generated from the toxic cascade of 
events induced by the toxic aggregates and that 
could be transferred from damaged to healthy 
cells. Finally, given the potential highly toxic and 
seeding-competent nature of the fibrillar oligomers 
generated during the aggregation reaction, in 
contrast to the seeding-deficient features of the 
kinetically trapped oligomers used in this study, as 
well as their high efficiency in enabling cell 
internalization compared to the fibrillar species, 
we hypothesize that these species are also likely to 
be important players in the development and 
spreading of disease. Indeed, we have recently 
observed that the interaction of extracellular short 
fibrillar species with cells results in the generation 
of on-pathway oligomers that are readily 
internalized (manuscript under review) and that 
could therefore efficiently seed the intracellular 
formation of new toxic aggregates. Overall, our 
results highlight the importance of fibrillar 
aggregates of α-synuclein in the induction of PD-
related phenotypes. Future studies to examine the 
mechanisms by which larger inclusions can 
fragment within the cell to become new and 
efficient nuclei for the propagation of α-synuclein 
inclusions and disease phenotypes will be of great 
interest, including disaggregation by chaperones or 
lysosomal proteases (40).  
Our results suggest that inhibiting the 
accumulation of small fibrillar α-synuclein 
fragments generated either during the process of 
protein aggregation or by the fragmentation or 
disaggregation of longer fibrils, have the potential 
to be a therapeutic strategy against PD 
progression. Indeed, immunotherapy using 
antibodies raised against α-synuclein are in phase 
II clinical trials (6). However, antibodies that are 
not selective for fibrillar α-synuclein also reduce 
the total concentration of α-synuclein, and may 
have deleterious effects because decreasing levels 
of α-synuclein impairs dopamine transmission 
(41,42). Antibodies that selectively target fibrillar 
aggregates and reduce their ability to spread from 
cell-to-cell could therefore reduce the rate of 
disease propagation. One example is BIIB054 
which selectively binds fibrillar α-synuclein (43), 
and in mouse models of PD, intraperitoneal 
injections of this antibody inhibited inclusion 
formation, dopamine neuron loss, and defects in 
motor behavior.  
It has been shown that formation of α-
synuclein oligomers in vivo by expression of 
human α-synuclein pathological variants using 
lentivirus induces loss of dopamine neurons (44). 

















parallel β-sheet structure, while the fibrillar 
structures are parallel, and so they are unable to 
elongate as they are kinetically trapped.  It is likely 
that oligomers containing a parallel ß-sheet 
structure are transient species involved in the 
formation of fibrils and are therefore able to 
elongate and proliferate. In addition, it is also 
likely that a range of different types of oligomeric 
species exist in vivo, including species bearing 
post-translational modifications, which are likely 
to share with the fibrillar species the ability to 
disrupt membranes and perturb other cellular 
processes such mitochondrial function (45,46). 
Overall, our data highlight the importance of 
precise biophysical definitions of the aggregated 
forms of α-synuclein that are responsible for the 
major events of dysfunction related to PD. In this 
study, injection of the small fibrillar fragments 
(70 nm in length) produced p-α-synuclein 
inclusions, neuronal loss and motor dysfunction. 
The fibril preparation, similar to that used in 
previous studies (5,30) containing longer 
fragments (40-225 nm) produced p-α-synuclein 
inclusions, but did not cause significant dopamine 
neuron loss or behavioral phenotypes at three 
months following injections. This result indicates 
that fibril preparations enriched for small 
fragments will produce the most robust 
phenotypes. Although the fibril model is becoming 
widely accepted for reproducing PD-like 
pathology, variability has been reported in 
obtaining phenotypes which could be caused by 
heterogeneous fibril preparations with a wide 
range of fibril sizes.  
Although the length of fragments does not 
substantially influence the seeding of fibril 
formation in vitro, smaller fragments are required 
for seeding of α-synuclein pathology in neurons 
and in the brain. This is likely to be because the 
smaller fragments bind more efficiently to cell 
surface receptors such as Lag3, Na+K+ATPase and 
heparin sulfate proteoglycans, and only the smaller 
fragments can be internalized by endocytosis (47-
49).  Furthermore, smaller fragmented fibrils are 
the most likely species to be released from neurons 
and to propagate throughout the brain.  
Our study adds to the results of earlier 
investigations that demonstrated that aggregates 
consisting solely of α-synuclein can generate PD 
phenotypes (5,16,30,31,50). However, in the 
future, it will be of great interest to characterize 
the structural properties of aggregates purified 
from diseased brains. Interestingly, brain extracts 
from patients with multiple system atrophy (MSA) 
have been reported to be more effective than those 
from PD brains at inducing α-synuclein inclusion 
formation and disease spreading when injected 
into experimental animals (51,52). α-Synuclein 
species involved in Lewy Body disease may bind 
receptors in the cortex and limbic regions more 
readily than do species involved in PD, which may 
bind more efficiently to receptors in the SNc. 
Future studies are required to determine how 
different aggregates contribute to specific disease 
phenotypes. Overall, our findings indicate that 
small fibrillar aggregates of α-synuclein are 
necessary for inducing pathology and spreading, 
and suggest that therapeutics should aim to reduce 
formation and accumulation of such species.  
 
Experimental Procedures 
Animals. All animal protocols were performed at 
AAALAC accredited sites and approved by the 
University of Alabama at Birmingham 
Institutional Animal Care and Use Committee. 
C57BL/6 J male mice were obtained from Jackson 
laboratories and housed in groups of no more than 
five animals per cage. Food and water were 
accessible 24 h, and animals were kept on a 12 h 
light/dark cycle.  
Preparation of α-synuclein species. α-synuclein 
monomer was purified according to previously 
published protocols (53). The presence of 
endotoxin was detected using the Pierce LAL 
chromogenic endotoxin quantitation kit and 
cleaned using Pierce high capacity endotoxin 
removal spin columns. Endotoxin levels were 
measured to be less than 0.0113 ng/mL. α-
Synuclein fibrils were prepared as previously 
published(53). Before surgeries, fibrils were 
sonicated using a 1/8” probe tip sonicator, (Fisher 
cat no.  FB120110) at 30%  power, for 30 sec 
total, 1 sec on, 1 sec off. Short fibrils were isolated 
using an EMD Millipore Millex 0.22 uM filter 
unit. Immediately before injections of monomeric 
α-synuclein, α-synuclein protein was spun at 
20,000g at 4ºC. β-sheet kinetically trapped α-
synuclein oligomers were freshly prepared as 
described previously (7,13,14). Briefly, 6 mg of 
lyophilized protein was resuspended in PBS buffer 

















1. The solution was filtered through a 0.22 μm 
cutoff filter and subsequently incubated at 37 °C 
for 24 h in stationary mode and without agitation. 
Small numbers of fibrillar species formed during 
the incubation were removed by 
ultracentrifugation for 1 h at 90,000 rpm (using a 
TLA-120.2 Beckman rotor; 288,000g). The excess 
of monomers and small oligomers in the sample 
was then removed by means of several filtration 
steps using 100 kDa cutoff membranes, which 
resulted in the enrichment and concentration of the 
oligomeric α-synuclein species. The oligomers 
prepared in this manner have been found to be 
stable for many days (7). They were shipped from 
Cambridge the same day of preparation and 
injected the day of receipt (one/two days after 
preparation) to ensure a stable, characterized 
conformation.  
Biophysical characterization of α-synuclein 
conformers. A comparative morphological and 
structural analysis of the different conformers has 
been performed using a variety of complementary 
biophysical techniques, and a detailed structural 
analysis has recently been carried out with 
oligomers of human α-synuclein using both cryo-
EM and solution and solid-state NMR 
spectroscopy (7,14). TEM images were obtained 
using a Philips CEM100 transmission electron 
microscope (CAIC, University of Cambridge UK). 
The samples were applied to Formvar carbon 
coated nickel grids, washed with ddH2O and 
negatively stained with 2% (w/v) uranyl acetate. 
AFM images were acquired using tapping mode in 
a Multimode 8 atomic force microscope (Bruker, 
Massachusetts, USA). The different α-synuclein 
species (0.1-1 μM, 10 μL) were applied onto a 
layer of freshly cleaved mica and allowed to air-
dry. The samples were washed with water to 
remove any salts and dried again before imaging. 
Images were processed with Gwyddion open 
source software (http://www.gwyddion.net). 
Sedimentation velocity measurements using AUC 
were carried out at 20 °C at 38,000 to 43,000 rpm 
(106,750 to 136,680 × g) by using a Beckman-
Coulter Optima XL-I analytical ultracentrifuge 
with an An-50 Ti rotor (Beckman-Coulter, Brea, 
CA, USA). The sedimentation coefficient 
distributions, corrected to standard conditions by 
using the SEDNTERP program (54), were 
calculated via least-squares boundary modeling of 
sedimentation velocity data using the c(s) and 
lsg*(s) methods, as implemented in the SEDFIT 
program (www.analyticalultracentrifugation.com). 
FTIR spectra of the different α-synuclein species 
(100-400 μM) were acquired in PBS and analyzed 
in a Bruker BioATRCell II using a Bruker 
Equinox 55 FTIR spectrophotometer (Bruker 
Optics Limited, UK) equipped with a liquid 
nitrogen cooled mercury cadmium telluride 
(MCT) detector and a silicon internal reflection 
element (IRE). For each spectrum, 256 
interferograms were recorded at 2 cm–1 resolution. 
Data processing of the amide I region (1720-1580 
cm-1) was performed with the Opus software 
package (Bruker Optics Limited, UK) and 
consisted of a background subtraction of the buffer 
spectrum, atmospheric compensation and baseline 
subtraction. All absorbance spectra were 
normalized for comparison. Far-UV CD spectra of 
the different α-synuclein species were acquired at 
20 °C between 200 nm and 250 nm, using a scan 
speed of 50 nm min-1 and a bandwidth of 1 nm. 10 
accumulations were recorded for each sample, 
using a 1 mm path length cuvette and a J-810 
Jasco spectropolarimeter (Tokyo, Japan), equipped 
with a thermostated cell holder. The signal was 
converted to mean residue ellipticity (M.R.E.). 
ThioT fluorescence measurements were performed 
in a 2 mm x 10 mm path length cuvette, using a 
Varian Cary Eclipse fluorimeter (Palo Alto, CA, 
USA) in a temperature-controlled cell holder, 
exciting the sample at 446 nm and recording the 
emission fluorescence spectrum between 460 to 
600 nm (5nm slitwidths). Each protein species (10 
μM) was incubated with ThioT (50 μM, 416nm = 
26620 M-1 cm-1) for 30 min before performing the 
measurement. For the seeding experiments, 10µM 
of each protein species (or 5µM in the case of the 
cross-seeding experiments) were added to a 
solution of 100 µM α-synuclein monomer, 50µM 
ThioT and 0.02% (w/v) sodium azide. The ThioT 
fluorescence was recorded in a BMG Fluostar 
Optima (BMG LABTECH, Aylesbury, Bucks, 
UK) using a excitation filter of 440 nm an and 
emission filter of 480 nm, at a constant 
temperature of 37 °C. 
Primary neurons were plated at 100,000 neurons 
per well in a 24 well tray onto poly-d-lysine 
coated coverslips and maintained in Neurobasal 
media, Glutamax, and B27 as previously 
described. The different conformers of α-synuclein 

















final concentration of 70 nM. Neurons were fixed 
7 days later and immunofluorescence to p-α-
synuclein (Abcam) and tau (Dako) was performed 
as previously described (4).   
Internalization assay was essentially performed as 
described (29) with some modifications. We thus 
generated Alexa 488 labeled fibrils and oligomers 
using the α-synuclein mutant E122C in order to 
incorporate the fluorophore at the upstream 
position of the recognized C-terminal truncation 
sites. E122C α-synuclein was purified and labeled 
using Life technologies Alexa Fluor 488 C5 
maleimide. The labelled protein was purified from 
free dye using a P10 desalting column and a 
Sephadex G25 matrix.  To perform the 
internalization experiments, primary neurons were 
incubated for 30 minutes in cold PBS containing 
α-synuclein-Alexa488 fibrils or oligomers (final 
concentration 70 nM) to allow the species to bind 
the plasma membrane. The neurons were then 
transferred to 37°C to allow internalization. 
Extracellular α-syn-Alexa488 fibrils were 
quenched with freshly made trypan blue, final 
concentration 1 mM in PBS. Images were captured 
using a Zeiss Axio Observer Z1 with Colibri LED 
illumination. The excitation/emission was 470/550 
nm for the fibrils and 560/630 nm for trypan blue. 
The average intensity of each frame captured was 
quantified using Fiji and normalized to the 
fluorescence signal from trypan blue bound to the 
neuronal membrane.  
Surgeries. Surgeries were performed using 
C57BL6/J mice aged two to four months using a 
digital stereotaxic frame (David Kopf). For the 
duration of surgery, mice were deeply anesthetized 
with vaporized isoflurane on a gas mask fitted to a 
digital stereotaxic frame. Mouse respiration was 
monitored throughout the procedure. Proteins for 
injection were drawn to a gas-tight syringe with a 
26s gauge needle (Hamilton) and controlled by a 
digital pump. Two μL of protein were injected and 
subsequent withdrawal of needle occurred over the 
course of 12 min. Solutions were injected into the 
right dorsal striatum using the following 
coordinates: 0.2 mm anterior and 2.0 mm lateral to 
the Bregma, and 2.6 mm ventral relative to the 
skull. Scalp incisions were closed with EZ-Clips 
(FisherSci).  
Immunohistochemistry and 
immunofluorescence. Mice injected with various 
α-syn conformations were anesthetized  post 
injection with isofluorane and transcardially 
perfused with a saline solution (0.9% NaCl, 
0.005% sodium nitroprusside, and 10 units/mL 
heparin sodium) followed by freshly prepared 4% 
paraformaldehyde (PFA) buffered in phosphate 
buffered saline (PBS). Brains were removed, 
postfixed for 24 h in 4% PFA and PBS solution, 
floated into 30% sucrose PBS solution for up to 
three days, frozen in methylbutane solution (−50 
°C), and stored at −80 °C. Brain tissue was 
sectioned at 40 μM with a freezing microtome. 
Immunohistochemistry and immunofluorescence 
was performed as described previously (55). 
Antibodies included: p-α-synuclein (EP1536Y 
(Abcam)) (56), tyrosine hydroxylase (Abcam), 
dopamine transporter (a generous gift from Dr. 
Allan Levey, Emory University (57). For the DAT 
and TH immunofluorescence in the striatum, 
confocal images of coronal sections (Bregma: -0.5 
mm anterior/posterior) were captured, and Image J 
was used to quantify the integrated intensity of the 
dorsal portion of the striatum. 
Behavior Assays. All behavioral tests were 
performed with the help of our UAB Neuroscience 
Behavioral Core. Mice were acclimated to the test 
environment for at least 30 min prior to testing and 
were given at least a 1-day rest between each test. 
Open Field Test Each mouse was placed at the 
side of a 100 × 100 × 50 cm white Plexiglass open 
field. A computerized tracking system 
(Ethovision) recorded movement for 5 minutes 
from which we derived the following: the amount 
of time spent in the center of the test apparatus, 
and the velocity of movement. Cylinder test  Mice 
were placed in a covered plexiglass cylinder with 
activity recorded for 5 min by Ethovision software 
on a camera positioned underneath the cylinder. 
An experimenter blinded to the treatment 
conditions scored each video. The following 
behaviors were scored: number of rears, front limb 
steps, hind limb steps, and total steps (37). Pole 
Test Mice were placed on top of a wooden pole 
(diameter 1 cm; height 50 cm) wrapped in chicken 
wire. Each subject completed 5 trials with a 1-
minute rest between each trial. Time to turn with 
nose facing down and time to reach the bottom of 
the pole were recorded and combined to derive the 
total time to descend. If a mouse did not climb 
down the pole after 2 min, the trial time was not 
included in that animal’s average total time to 

















top elevated 50 cm above a cage filled with 
bedding. The cage lid was shaken slightly and 
flipped over to measure latency to fall over the 
course of 3 trials ( > 1 min rest between each trial). 
A trial less than 10 seconds was performed again, 
and trials were concluded at 3 min if a mouse was 
still hanging. 
Stereology Stereology was completed using an 
Olympus BX51 microscope and StereoInvestigator 
software (MBF Biosciences) using the UAB 
Neuroscience Molecular Detection and Stereology 
Core. Contours were drawn around 6-7 serial 
sections containing SNc. Unbiased stereological 
estimation of total TH-positive neurons in the SNc 
contralateral and ipsilateral to injection was 
performed using the Optical Fractionator probe by 
an investigator blinded to experimental conditions. 
Statistical Analyses. Data were analyzed using 
GraphPad Prism. One-way or two-way ANOVA 
were performed. Outliers were identified using the 
ROUT method in Graphpad Prism. The only data 
in which 2 outliers were identified were in the 
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Monomer N/A Random coil N/A No No 








70 60% β-sheet Parallel Yes Yes 
Oligomers (“O”) 54 30% β-sheet Anti-Parallel No No 
 

























Motor Cortex 1.6 1.1 
Somatosensory Cortex 1.6 1 
Insular Cortex 1.6 1 
SNc 1.6 0 
Auditory Cortex 1.4 0.9 
Lateral Orbital Cortex 1.3 0.9 
Amygdala 1.3 0.6 
Ectorhinal Cortex 1.3 0.9 
Striatum 1.1 0.5 
Cingulate Cortex 1.0 1.0 
Visual Cortex 1.0 0.4 
Piriform Cortex 1.0 0.5 
Nucleus Accumbens 0.4 0.4 
Retrosplenal Cortex 0.7 0.3 
Subiculum .6 0 
Hippocampus 0.4 0 
Mammillary nucleus 0.5 0.1 
Olfactory Tubercle 0.2 0 
Fimbria 0 0 
Cerebellar Flocculus 0 0 
Colliculus 0 0 
 
Table 2. Mice received unilateral striatal injections of F-S and were perfused three months later. 
Immunohistochemistry was performed on brain sections using an antibody to p-α-synuclein. The 
abundance of inclusions in these brain areas was rated on a scale from 0 to 3 (see Supplementary material 
1) and the brain areas are listed in order of average score. Brains from nine independent mice were scored 




















Figure 1. Morphological characterization of the mouse α-synuclein species used in the in vivo mouse 
studies. TEM and AFM images of fibrils (F-L) (A,B), sonicated fibrils (F-M) (E,F), sonicated fibrils 
enriched in short fragments (F-S) (I,J), and oligomers (O) (M,N). (C-P).AFM was used to quantify the 
length and height of each species shown in the histograms.  
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Average Length = 120 nm
Distribution: 40-225 nm
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Figure 2. Structural characterization of α-synuclein species used in the in vivo mouse studies. (A) 
AU sedimentation velocity measurement of human (blue dashed line) and mouse oligomers (orange line) 
shows 10S and 15S species. (B) FTIR spectra shows that F-L, F-M, and F-S species are primarily 
composed of parallel β-sheet (band at 1,620-1630), and that the oligomeric (mouse and human) species 
are primarily antiparallel (band at 1620-1630 cm-1 and shoulder at 1695cm-1). The mouse and human 
oligomers have β-sheet structure of about 40% and 65%, respectively. (C) CD show that β-sheet content 
of oligomers (mouse and human) are intermediate between monomer and fibrils. (D) ThioT binding 
shows that the fibrils adopt an amyloid conformation, the oligomers show limited ThioT binding and 

















Figure 3. Seeding ability of the difference assembled forms of  α-synuclein species in vitro and in 
primary neurons. (A,B) Monomer (100 µM) was incubated with 5 µM fibrillar or oligomeric seeds and 
the fluorescence of samples incubated with ThioT was quantified over time. (C,D) For the primary 
hippocampal neurons, 70 nM of F-L, F-M, F-S or oligomers were added to the neurons and after seven 
days, the neurons were fixed and inclusion formation was visualized using an antibody to p-α-synuclein 
(green). Immunofluorescence for tau (magenta) shows the distribution of axons (Scale bar = 50 µM). 
Image J was used to quantify the percent area occupied by p-α-synuclein fluorescence normalized to the 
area occupied by tau fluorescence. The data are presented as the mean ± SEM.  (E) Primary hippocampal 
neurons were pre-incubated with Alexa 488 tagged F-L, F-S or O for 30 min at 4°C to allow binding to 
the cell surface. The neurons were then incubated for 15 or 30 min at 37ºC to allow internalization. 
Fluorescence of external α-synuclein-Alexa 488 was quenched using trypan blue. Images show 
representative α-synuclein-Alexa 488 fibrils or oligomers. When trypan blue binds to proteins on the cell 
surface it fluoresces at 560 nm which is shown in the images as magenta (Scale bar = 50 µM).  The 
fluorescence intensity of Alexa 488 from 10 fields per condition was quantified and normalized to trypan 



















Figure 4. Inclusion formation in the mouse brain after injection of different forms of α-synuclein. 
C57BL/6J mice received unilateral striatal injections of two µL of soluble monomer (300 µM), F-L (150 
µM), F-M (150 µM), F-S (150 µM) and O (300 µM). After three months, mice were perfused and 
immunohistochemistry was performed using an antibody to p-α-synuclein. Representative images from 
the SNc (A) and amygdala (B) are shown. Arrowheads indicate inclusions in the soma and arrows 
indicate Lewy neurite-like inclusions. (C) The abundance of inclusions were measured by an investigator 
blinded to experimental conditions (Supporting Material 1). Numbers of mice: monomer (12), F-L (11), 
F-M (12), F-S (11), O (15). Data are shown as the mean score ± SEM and were analyzed using a two-way 
ANOVA, α-synuclein species/cingulate F(2,30) = 37.85, p < 0.0001; α-synuclein species/motor cortex 
F(2,30) = 7.9, p < 0.002; α-synuclein species/insular cortex F(2,30) = 22.3, p < 0.0001; α-synuclein 
species/striatum F(2,30) = 8.5, p < 0.001; α-synuclein species/amygdala F(2,30) = 6.6, p = 0.004; α-
synuclein species/SNc F(2,30) = 6.2, p < 0.005. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Scale 

















Figure 5. Appearance of p-α-synuclein inclusions in brain areas that project to the striatum. Fibrils 
and retrotracer beads were co-injected unilaterally into the striatum. After, one (N=3), two (N=3) or 4 
weeks (N=3), mice were perfused and immunofluorescence to p-α-synuclein (green) was performed. The 
retrotracer beads are shown in red and the merged images include p-α-synuclein, retrotracer beads and 
















Figure 6. Quantitation of TH-positive neurons in the SNc, and DAT terminals in striatum following 
unilateral striatal injections of different α-synuclein species. C57BL/6J mice received unilateral 
striatal injections of two µL of soluble monomer (300 µM), F-L (150 µM), F-M (150 µM), F-S (150 µM) 
and O (300 µM). After three months, the mice were perfused and immunostaining was performed. 
Numbers of mice: monomer (12), F-L (11), F-M (12), F-S (11), O (15) (A) Representative images of 
tyrosine hydroxylase immunohistochemistry in the SNc of monomer and F-S injected mice. (B) Unbiased 
stereology of tyrosine hydroxylase positive neurons performed by an investigator blinded to experimental 
conditions. Data are shown as the mean counts ± SEM and analyzed using a two-way ANOVA, α-
synuclein species F(5,67) = 2.7, p = 0.03. (C) Immunofluorescence performed using antibodies for both 
DAT and an Alexa-488-goat anti-rat secondary (shown above), and TH and an Alexa-555-goat anti-
chicken secondary. Images were captured using confocal microscopy. Representative images of DAT in 
the striatum from monomer and F-S injected mice are shown. See also Supplemental Figure 5 which 
shows TH immunofluorescence from the same monomer striatal section shown in this figure, and 
quantitation of TH in the striatum. (D) Image J was used to quantify the integrated fluorescence intensity 
of DAT in the striatum. Data are shown as the mean counts ± SEM and analyzed using a two-way 
ANOVA, α-synuclein species F(3,43) = 5.7 , p = 0.002. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 


















Figure 7. Motor behavior of mice following unilateral striatal injections of different α-synuclein 
species. C57BL/6J mice received unilateral striatal injections of two µL of monomer (300 µM), F-L (150 
µM), F-M (150 µM), F-S (150 µM) and O (300 µM). Three months later, mice were subjected to the 
following behavior tests: open field, pole test, cage hang, cylinder test (modified for mice).  Numbers of 
mice for pole test, cage hang, open field: monomer (12), F-L (11), F-M (12), F-S (11), O (15). Numbers 
of mice for cylinder test: monomer (10), F-L (10), F-M (10), F-S (10), O (10). The data were analyzed by 
one-way ANOVA: pole test F(4,69) = 4.7, p = 0.002; cage hang F(4,66) = 2.86, p = 0.03;  open 
field/%time center F(4,69) = 1,1, p = NS; open field/velocity F(4,69) = 0.6, p = NS; hind limb steps 
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